Anika Therapeutics Inc - Asset Resilience Ratio
Anika Therapeutics Inc (ANIK) has an Asset Resilience Ratio of 11.17% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Anika Therapeutics Inc (ANIK) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2022)
This chart shows how Anika Therapeutics Inc's Asset Resilience Ratio has changed over time. See ANIK net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Anika Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Anika Therapeutics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $36.74 Million | 11.17% |
| Total Liquid Assets | $36.74 Million | 11.17% |
Asset Resilience Insights
- Moderate Liquidity: Anika Therapeutics Inc has 11.17% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Anika Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Anika Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Dermapharm Holding SE
XETRA:DMP |
Drug Manufacturers - Specialty & Generic | 1.23% |
|
China Animal Husbandry Industry Co Ltd
SHG:600195 |
Drug Manufacturers - Specialty & Generic | 3.81% |
|
Daewoong Pharma
KO:069620 |
Drug Manufacturers - Specialty & Generic | 0.19% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
Annual Asset Resilience Ratio for Anika Therapeutics Inc (1999–2022)
The table below shows the annual Asset Resilience Ratio data for Anika Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 9.92% | $34.63 Million | $349.13 Million | +9.23pp |
| 2020-12-31 | 0.68% | $2.50 Million | $365.61 Million | -7.63pp |
| 2019-12-31 | 8.31% | $27.48 Million | $330.71 Million | -16.77pp |
| 2018-12-31 | 25.08% | $69.97 Million | $278.99 Million | +16.59pp |
| 2017-12-31 | 8.49% | $24.00 Million | $282.62 Million | -0.04pp |
| 2016-12-31 | 8.53% | $20.50 Million | $240.25 Million | -3.24pp |
| 2015-12-31 | 11.77% | $27.75 Million | $235.75 Million | +8.29pp |
| 2014-12-31 | 3.48% | $6.75 Million | $194.00 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $156.04 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $142.07 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $132.84 Million | -- |
| 2007-12-31 | 4.41% | $3.50 Million | $79.50 Million | +0.67pp |
| 2003-12-31 | 3.74% | $818.00K | $21.87 Million | -8.71pp |
| 2002-12-31 | 12.45% | $2.50 Million | $20.09 Million | -4.98pp |
| 2001-12-31 | 17.43% | $3.99 Million | $22.92 Million | -17.22pp |
| 2000-12-31 | 34.65% | $10.04 Million | $28.98 Million | +9.42pp |
| 1999-12-31 | 25.23% | $8.20 Million | $32.50 Million | -- |
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more